Evidence map›Paper›PMID 39774927›Full record

ArticleAnnals of hematology2025

A prognostic index for advanced-stage extranodal natural killer/T-cell lymphoma: A multicenter study.

Xiaojie Fang, Fenglan Zhou, Sheng Ye, Hongyu Zhang, Hongqiang Guo, Xinggui Chen, Chaoyong Liang, Xingxiang Pu, Yabing Cao, Quanguang Ren and 4 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xiaojie Fang *Department of Medical Oncology, State Key Laboratory of Oncology in Southern China, and Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Fenglan Zhou *Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, No. 55, Section 4, South Renmin Road, Chengdu, 610042, China.
Sheng YeDepartment of Medical Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Hongyu ZhangDepartment of Medical Oncology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China.
Hongqiang GuoDepartment of Medical Oncology, He Nan Cancer Hospital, Zhengzhou, China.
Xinggui ChenDepartment of Medical Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Chaoyong LiangDepartment of Medical Oncology, Guangxi Cancer Hospital, Nanning, China.
Xingxiang PuDepartment of Medical Oncology, Hunan Cancer Hospital, Changsha, China.
Yabing CaoDepartment of Medical Oncology, Kiang Wu Hospital, Macau, China.
Quanguang RenDepartment of Medical Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xiaoqian LiDepartment of Medical Oncology, Shandong Cancer Hospital, Jinan, China.
Linzhu ZhaiDepartment of Medical Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
He HuangDepartment of Medical Oncology, State Key Laboratory of Oncology in Southern China, and Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Huangming HongDepartment of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, No. 55, Section 4, South Renmin Road, Chengdu, 610042, China. honghuangming@scszlyy.org.cn.

Funding

National Natural Science Foundation of China 82270198Outstanding Young Scientific and Technological Talents Fund of Sichuan Province 2022JDJQ0059
6 · The paper itself

Abstract

Advanced-stage extranodal natural killer/T-cell lymphoma (ENKTL) is a highly heterogeneous disease with very poor prognosis. All commonly utilized prognostic models incorporated both early-stage and advanced-stage patients in the modeling process. This study aim to design a prognostic model specifically for advanced-stage ENKTL, providing risk stratification in affected patients. We analyzed 291 patients with stage III/IV ENKTL receiving asparaginase-based chemotherapy from 8 institutions to develop a new prognostic model and validate it in an independent cohort consisted of 221 patients from 4 additional hospitals. The prognostic model included three independent variables based on a multivariate analysis for overall survival (OS): age, bone marrow invasiveness and visceral organ involvement. We identified three different risk groups: group 1, no adverse factors; group 2, one factor; and group 3, two or three factors, which were associated with 5-year OS rates of 66.0%, 32.3%, and 20.0%, respectively (P < 0.001). The prognostic index of natural killer lymphoma (PINK) and nomogram-revised risk index (NRI) were unsatisfactory for stratifying these patients. These results were validated and confirmed in an independent cohort. This newly proposed model can be used to guide risk-adapted treatment for advanced stage ENKTL.

Indexed as

Lymphoma, Extranodal NK-T-CellAdolescentAdultAgedAged, 80 and overAsparaginaseCohort StudiesFemaleHumansMaleMiddle AgedNeoplasm StagingNomogramsPrognosisRetrospective StudiesSurvival RateAsparaginaseAdvanced-stageExtranodal natural killer/T-cell lymphomaPrognostic modelRisk stratification

Identifiers

PMID39774927

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.